Synmosa Biopharma
Synmosa Biopharma Corporation, a specialty pharmaceutical company, researches, develops, manufactures, markets, and distributes pharmaceutical and healthcare products under the Synmosa brand in Taiwan. The company offers its products in various therapeutic areas, including cardiovascular, respiratory, urology, sex hormone, and oncology. The company also provides its products in various forms, suc… Read more
Synmosa Biopharma (4114) - Total Liabilities
Latest total liabilities as of September 2025: NT$4.12 Billion TWD
Based on the latest financial reports, Synmosa Biopharma (4114) has total liabilities worth NT$4.12 Billion TWD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Synmosa Biopharma - Total Liabilities Trend (2015–2024)
This chart illustrates how Synmosa Biopharma's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Synmosa Biopharma Competitors by Total Liabilities
The table below lists competitors of Synmosa Biopharma ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Clean Science and Technology Limited
NSE:CLEAN
|
India | ₹1.84 Billion |
|
BLUE LABEL
MU:5TP
|
Germany | €11.54 Billion |
|
Suzhou HYC Technology Co Ltd
SHG:688001
|
China | CN¥2.28 Billion |
|
Aditya Birla Fashion and Retail Limited
NSE:ABFRL
|
India | ₹109.51 Billion |
|
Personalis Inc
NASDAQ:PSNL
|
USA | $71.42 Million |
|
Digital Turbine Inc
NASDAQ:APPS
|
USA | $663.57 Million |
|
Vox Royalty Corp. Common Stock
NASDAQ:VOXR
|
USA | $22.24 Million |
Liability Composition Analysis (2015–2024)
This chart breaks down Synmosa Biopharma's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.45 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.48 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.29 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Synmosa Biopharma's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Synmosa Biopharma (2015–2024)
The table below shows the annual total liabilities of Synmosa Biopharma from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$3.91 Billion | +7.65% |
| 2023-12-31 | NT$3.63 Billion | -20.34% |
| 2022-12-31 | NT$4.55 Billion | +7.87% |
| 2021-12-31 | NT$4.22 Billion | -4.55% |
| 2020-12-31 | NT$4.42 Billion | +12.91% |
| 2019-12-31 | NT$3.92 Billion | +28.03% |
| 2018-12-31 | NT$3.06 Billion | -13.54% |
| 2017-12-31 | NT$3.54 Billion | +45.22% |
| 2016-12-31 | NT$2.44 Billion | +54.36% |
| 2015-12-31 | NT$1.58 Billion | -- |